Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
8th grade Avg
|
New words:
absolute, adjunct, age, ahead, area, array, ASV, atazanavir, battle, biopharma, biotechnology, boosting, broad, cetuximab, Chamber, Chester, cirrhotic, cobicistat, committed, comprised, comprising, congenital, core, culture, cure, Daewoong, DCV, dedicated, deficiency, diet, disciplined, disproxil, divestiture, Dual, element, EMA, encourage, entirety, equivalent, evolution, evolve, evolving, exceeded, facilitate, Farxiga, fundamental, goodwill, greatest, Hanmi, HCV, immune, immunology, Indiana, interferon, introduced, iPierian, KIPO, Korean, labeling, leptin, long, MAA, manner, Mount, neurodegenerative, Ohio, older, orderly, palsy, Pen, pharmacokinetic, pioneering, population, preclinical, prejudice, purpose, pursue, pursuing, redeemed, redemption, ribavirin, rolling, similarly, sNDA, sofosbuvir, specialty, standalone, strongly, sulfate, supranuclear, Taxol, therapeutic, tolerated, undelivered, unlock, unmet, unrealized, Vernon, voluntarily, West, Xigduo
Removed:
abandonment, academic, accessible, acted, adding, administered, advanced, advancing, aggregation, agonist, amendment, America, American, amortizing, analgesic, analyzing, angiotensin, antagonist, anticoagulant, Asia, Asian, Audit, austerity, automatic, avoidance, award, aware, base, BBB, blocker, Book, borne, breast, build, calculating, cardiac, categorized, classification, cocommercialization, codevelop, codeveloped, coincide, collateral, comarketing, comparison, complement, considerably, continuously, controlling, conventional, copromotion, corroborated, cotransporter, counterparty, criminal, criteria, Dafalgan, daily, defend, deposit, derivative, description, detail, diabetic, dispensed, distributor, diversified, DNA, document, dosage, duration, effort, EGFR, emergence, entering, entitled, equally, error, Estrace, evidence, exclusive, expand, expiring, face, failed, fee, Florence, fluctuate, force, foundation, framework, France, FRS, fund, governance, gradual, hemostat, hierarchy, highest, Historically, home, hormone, hypertension, identified, II, ImClone, immunosuppressive, IMS, increasingly, industry, infection, Influenced, informing, ingredient, Inhibitex, Interbank, internally, invoiced, irbesartan, issuance, issue, issuing, Italian, ixabepilone, KGaA, kidney, Kingdom, Kluwer, lack, large, Latin, left, lesser, limiting, listed, LLC, location, London, mail, maintain, managed, managing, margin, markup, matrix, maximum, Medarex, meeting, methodology, metreleptin, mitigated, monitored, multiplying, National, necitumumab, negatively, nephropathy, network, newer, norm, Nulojix, Offered, operational, ordering, original, ownership, parenterally, participated, partnership, placement, platelet, prescriber, principally, priority, profitability, projection, qualify, Racketeer, rated, ratio, reacquire, realize, receivable, recombinant, refine, rejection, relied, renewed, responsibility, restructured, retail, retained, returning, revert, reviewing, robust, routine, SA, sampling, saxagliptin, security, seek, shipped, small, Source, specifically, spending, stay, streamlining, string, suffered, sufficient, Supplementary, supplied, surfaced, surgical, sustaining, terminal, terminating, territory, thereof, thrombin, topical, traded, trademark, trading, transformed, transition, transparency, transplant, treasury, unadjusted, unamortized, unchanged, unfunded, utilize, valuation, variability, vast, vigorously, volatility, warn, wholly, women, worked, XR, yield
Filing tables
Filing exhibits
BMY similar filings
Filing view
External links
EXHIBIT 12.
Computation of Earnings to Fixed Charges
Ratio of Earnings to Fixed Charges: | Three Months Ended March 31, 2014 | Year Ended December 31, | |||||||||||||||||
2013 | 2012 | 2011 | 2010 | ||||||||||||||||
Dollars in Millions | |||||||||||||||||||
Earnings | |||||||||||||||||||
Earnings from continuing operations before income taxes | $ | 985 | $ | 2,891 | $ | 2,340 | $ | 6,981 | $ | 6,071 | |||||||||
Less: | |||||||||||||||||||
Noncontrolling interest in pre-tax income of subsidiaries | |||||||||||||||||||
that have not incurred fixed charges | 4 | 36 | 844 | 2,323 | 2,074 | ||||||||||||||
Equity in net income of affiliates | 36 | 166 | 183 | 281 | 313 | ||||||||||||||
Capitalized interest | — | — | — | — | 8 | ||||||||||||||
Adjusted Income | 945 | 2,689 | 1,313 | 4,377 | 3,676 | ||||||||||||||
Add: | |||||||||||||||||||
Fixed charges | 66 | 255 | 227 | 190 | 201 | ||||||||||||||
Distributed income of equity investments | — | 149 | 229 | 283 | 313 | ||||||||||||||
Total Earnings | $ | 1,011 | $ | 3,093 | $ | 1,769 | $ | 4,850 | $ | 4,190 | |||||||||
Fixed Charges | |||||||||||||||||||
Interest expense | $ | 54 | $ | 199 | $ | 182 | $ | 145 | $ | 145 | |||||||||
Capitalized interest | — | — | — | — | 8 | ||||||||||||||
One-third of rental expense(1) | 12 | 56 | 45 | 45 | 48 | ||||||||||||||
Total Fixed Charges | $ | 66 | $ | 255 | $ | 227 | $ | 190 | $ | 201 | |||||||||
Ratio of Earnings to Fixed Charges | 15.32 | 12.13 | 7.79 | 25.53 | 20.85 |
(1) Rents included in the computation consist of one-third of rental expense which the Company believes to be a reasonable estimate of an interest factor in its leases.